Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02942888 · ClinicalTrials.gov registry record · NA
The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition
A NA study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT02942888: Completed NA study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT02942888 is a NA study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 46 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02942888, a NA study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of Niagen (nicotinamide riboside, vitamin B3), on NAD levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (MCI).
Primary Outcome
MoCA Value
Interventions
- DIETARY_SUPPLEMENT Nicotinamide riboside
- DIETARY_SUPPLEMENT Sugar Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2021-08-16 |
| Phase | NA |
What the finished NCT02942888 record still lists
NCT02942888 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Nicotinamide riboside is the first listed.
NCT02942888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02942888 about?
NCT02942888 is a clinical study titled "The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition". The purpose of this study is to determine the effects of Niagen (nicotinamide riboside, vitamin B3), on NAD levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (MCI).
What is the current status of trial NCT02942888?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2017-11-30. Estimated completion is 2021-08-16.
What interventions are being tested in trial NCT02942888?
The interventions under investigation include: Nicotinamide riboside (DIETARY_SUPPLEMENT), Sugar Pill (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02942888?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02942888's enrollment target sits among peer trials
46 1402nd of 2000 higher than 590 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI